The non-dilutive nature of the loan preserves shareholder value by avoiding the issuance of new shares, which can dilute existing ownership. This strategic financial maneuver is likely to be viewed positively by the market, as it demonstrates Sanara MedTech's ability to secure funding for growth while maintaining shareholder interests. The substantial amount of $55 million indicates significant growth initiatives that could enhance the company's competitive edge and market presence in 2024 and 2025.